Skip to main content

06-14-2018 | Pioglitazone | Article

Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies

Journal: Diabetology International

Authors: Juha Mehtälä, Houssem Khanfir, Dimitri Bennett, Yizhou Ye, Pasi Korhonen, Fabian Hoti

Publisher: Springer Japan




Studies investigating bladder cancer risk in pioglitazone-treated type 2 diabetes mellitus patients report conflicting results. Previous meta-analyses on this topic utilized publications prior to 2013. More long-term observational studies have been published since then. We reviewed the accumulated evidence and updated findings from previous meta-analyses.


This meta-analysis was based on a systematic review of peer-reviewed observational studies published prior to September 30, 2016. Eligible studies were identified using a specified MEDLINE search. References from included studies and from previous meta-analyses were screened for additional records. Meta-analysis hazards ratios were derived using a random-effects model. Several sensitivity analyses including hierarchical Bayesian meta-analysis with country-specific effects were conducted.


Of 363 identified records, 23 studies were included in this review and 18 in the actual meta-analyses. For bladder cancer outcome, the estimated effect size for ever vs. never use of pioglitazone was 1.16 [95% confidence interval (CI), 1.04–1.28]. In the cumulative dose and duration analyses, highest effect was observed in the highest/longest exposure group, but substantial heterogeneity was present. In the sensitivity analysis, only studies adjusted for lifestyle-related factors were included and the frequentist effect size was 1.18 (95% CI, 1.00–1.40, p = 0.054). However, the risk was not verified in the Bayesian framework with an effect size of 1.17 [95% credible interval (CrI), 0.94–1.54].


In line with previous meta-analyses, we observed a small but statistically significant association between ever (vs. never) use of pioglitazone and bladder cancer risk; however, causality is not established and alternative explanations cannot be ruled out.
World Health Organization. Global Report on Diabetes. 2016. http://​apps.​who.​int/​iris/​bitstream/​10665/​204871/​1/​9789241565257_​eng.​pdf?​ua=​1. Accessed 23 Aug 2016.
Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. http://​www.​cdc.​gov/​diabetes/​pubs/​statsreport14/​national-diabetes-report-web.​pdf. Accessed 23 Aug 2016.
American Diabetes Association. Economic Costs of Diabetes in the US in 2012. Diabetes Care. 2013;36:1033–46. https://​doi.​org/​10.​2337/​dc12-2625. CrossRefPubMedCentral
DeFronzo RA, Banerji M, Bray GA, et al. Actos now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009. https://​doi.​org/​10.​1186/​1472-6823-9-17. CrossRefPubMedPubMedCentral
DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15. https://​doi.​org/​10.​1056/​NEJMoa1010949. CrossRefPubMed
Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10–7. CrossRefPubMed
Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22:1395–409. CrossRefPubMed
Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251–7. PubMed
Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, Randomized Trial. J Clin Endocrinol Metab. 2004;89:6068–76. https://​doi.​org/​10.​1210/​jc.​2003-030861. CrossRefPubMed
Takeda Pharmaceuticals America, Inc. Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. 2009. http://​www.​actos.​com/​actospro/​home.​aspx. Accessed 12 Aug 2016.
Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34(6):1369–71. https://​doi.​org/​10.​2337/​dc10-2412. CrossRefPubMedPubMedCentral
Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916–22. https://​doi.​org/​10.​2337/​dc10-1068. CrossRefPubMedPubMedCentral
Tseng C-H. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35:278–80. https://​doi.​org/​10.​2337/​dc11-1449. CrossRefPubMedPubMedCentral
Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953–62. https://​doi.​org/​10.​1007/​s00125-012-2538-9. CrossRefPubMedPubMedCentral
Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645. CrossRefPubMedPubMedCentral
Fujimoto K, Hamamoto Y, Honjo S, et al. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;99:e21–3. https://​doi.​org/​10.​1016/​j.​diabres.​2012.​11.​013. CrossRefPubMed
Song SO, Kim KJ, Lee B-W, et al. The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. Diabetes Metab J. 2012;36:371–8. https://​doi.​org/​10.​4093/​dmj.​2012.​36.​5.​371. CrossRefPubMedPubMedCentral
Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ Can Med Assoc J J Assoc Medicale Can. 2012;184:E675–83. https://​doi.​org/​10.​1503/​cmaj.​112102. CrossRef
Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 2013;18:148–56. https://​doi.​org/​10.​1634/​theoncologist.​2012-0302. CrossRefPubMedPubMedCentral
Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30:1026–32. https://​doi.​org/​10.​1111/​dme.​12144. CrossRefPubMed
Turner RM, Kwok CS, Chen-Turner C, et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis: thiazolidinediones and bladder cancer. Br J Clin Pharmacol. 2014;78:258–73. https://​doi.​org/​10.​1111/​bcp.​12306. CrossRefPubMed
Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012;98:159–63. https://​doi.​org/​10.​1016/​j.​diabres.​2012.​05.​006. CrossRefPubMed
He S, Tang Y, Zhao G, et al. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:2095–102. https://​doi.​org/​10.​1007/​s13277-013-1278-x. CrossRef
Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58:493–504. https://​doi.​org/​10.​1007/​s00125-014-3456-9. CrossRefPubMed
Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265. https://​doi.​org/​10.​1001/​jama.​2015.​7996. CrossRefPubMed
Tuccori M, Filion KB, Yin H, et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016;352:i1541. CrossRefPubMedPubMedCentral
Korhonen P, Heintjes EM, Williams R, et al. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. BMJ. 2016. https://​doi.​org/​10.​1136/​bmj.​i3903. CrossRefPubMedPubMedCentral
von Hippel PT. The heterogeneity statistic I 2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015. https://​doi.​org/​10.​1186/​s12874-015-0024-z. CrossRef
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58. https://​doi.​org/​10.​1002/​sim.​1186. CrossRefPubMed
Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. https://​doi.​org/​10.​1136/​bmj.​327.​7414.​557. CrossRefPubMedPubMedCentral
Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis. J Clin Epidemiol. 2001;54:1046–55. https://​doi.​org/​10.​1016/​S0895-4356(01)00377-8. CrossRefPubMed
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101. CrossRefPubMed
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34. CrossRefPubMedPubMedCentral
Jin S-M, Song SO, Jung CH, et al. Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. J Korean Med Sci. 2014;29:238. https://​doi.​org/​10.​3346/​jkms.​2014.​29.​2.​238. CrossRefPubMedPubMedCentral
Hsiao F-Y, Hsieh P-H, Huang W-F, et al. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf. 2013;36:643–9. https://​doi.​org/​10.​1007/​s40264-013-0080-4. CrossRefPubMed
Mackenzie TA, Zaha R, Smith J, et al. Diabetes pharmacotherapies and bladder cancer: a medicare epidemiologic study. Diabetes Ther. 2016;7:61–73. https://​doi.​org/​10.​1007/​s13300-016-0152-4. CrossRefPubMedPubMedCentral
Shapiro S. Causation, bias and confounding: a hitchhiker’s guide to the epidemiological galaxy part 2. Principles of causality in epidemiological research: confounding, effect modification and strength of association. J Fam Plann Reprod Health Care. 2008;34:185–90. https://​doi.​org/​10.​1783/​1471189087847348​73. CrossRefPubMed
Greco T, Zangrillo A, Biondi-Zoccai G, et al. Meta-analysis: pitfalls and hints. Heart Lung Vessels. 2013;5:219–25. PubMedPubMedCentral
Chang C-H, Lin J-W, Wu L-C, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55:1462–72. https://​doi.​org/​10.​1002/​hep.​25509. CrossRefPubMed
Kuo H-W, Tiao M-M, Ho S-C, et al. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci. 2014;30:94–7. https://​doi.​org/​10.​1016/​j.​kjms.​2013.​09.​011. CrossRefPubMed
Han E, Jang S-Y, Kim G, et al. Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes. Medicine (Baltimore). 2016;95:e2786. https://​doi.​org/​10.​1097/​MD.​0000000000002786​. CrossRef
Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. JNCI J Natl Cancer Inst. 2012;104:1411–21. https://​doi.​org/​10.​1093/​jnci/​djs328. CrossRefPubMed
Tseng C-H. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35:278–80. https://​doi.​org/​10.​2337/​dc11-1449. CrossRefPubMedPubMedCentral
Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 2013;75:254–9. https://​doi.​org/​10.​1111/​j.​1365-2125.​2012.​04325.​x. CrossRefPubMed
Vallarino C, Perez A, Fusco G, et al. Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. Clin Drug Investig. 2013;33:621–31. https://​doi.​org/​10.​1007/​s40261-013-0106-9. CrossRefPubMedPubMedCentral
Lee M-Y, Hsiao P-J, Yang Y-H, et al. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease. PLoS One. 2014;9:e85479. https://​doi.​org/​10.​1371/​journal.​pone.​0085479. CrossRefPubMedPubMedCentral
Balaji V, Seshiah V, Ashtalakshmi G, et al. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab. 2014;18:425. https://​doi.​org/​10.​4103/​2230-8210.​131223. CrossRefPubMedPubMedCentral
Lewis JD, Habel L, Quesenberry C, et al. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer: proteinuria and bladder cancer diagnosis. Pharmacoepidemiol Drug Saf. 2014;23:636–45. https://​doi.​org/​10.​1002/​pds.​3619. CrossRefPubMed

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions